Neurocrine Biosciences Inc (NBIX)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 486,000 | 521,600 | 446,900 | 469,900 | 332,100 | 251,800 | 234,100 | 89,200 | 213,900 | 82,200 | 14,800 | 95,600 | 101,400 | 156,900 | 69,300 | 95,000 | 106,700 | 103,600 | 219,100 | 188,000 |
| Revenue (ttm) | US$ in thousands | 2,355,300 | 2,241,400 | 2,117,000 | 1,978,200 | 1,882,900 | 1,779,300 | 1,668,300 | 1,522,900 | 1,411,600 | 1,306,100 | 1,208,800 | 1,185,500 | 1,107,700 | 1,050,200 | 1,010,800 | 1,022,200 | 1,020,900 | 1,017,010 | 981,066 | 862,604 |
| Pretax margin | 20.63% | 23.27% | 21.11% | 23.75% | 17.64% | 14.15% | 14.03% | 5.86% | 15.15% | 6.29% | 1.22% | 8.06% | 9.15% | 14.94% | 6.86% | 9.29% | 10.45% | 10.19% | 22.33% | 21.79% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $486,000K ÷ $2,355,300K
= 20.63%
The pretax margin of Neurocrine Biosciences Inc has displayed fluctuations over the observed periods in the financial statements. The pretax margin represents the percentage of each dollar of revenue that the company retains as profit before taxes.
From March 31, 2020, to June 30, 2020, the pretax margin showed improvement, increasing from 21.79% to 22.33%. However, there was a significant decline in the pretax margin in the subsequent quarters, dropping to 10.19% by September 30, 2020, and further to 10.45% by December 31, 2020.
The trend continued into the first half of 2021, with the pretax margin falling to 6.86% by June 30, 2021. Notably, there was an increase in pretax margin to 14.94% by September 30, 2021. However, the improvement was short-lived, as the pretax margin decreased to 9.15% by December 31, 2021, and further to 8.06% by March 31, 2022.
The trend reversed in the second half of 2022, with the pretax margin climbing to 15.15% by December 31, 2022. The positive momentum continued into 2023, with the pretax margin increasing to 17.64% by December 31, 2023.
By the end of 2024, the pretax margin remained relatively stable, ranging between 20.63% and 23.75% for the last four quarters. Overall, the pretax margin of Neurocrine Biosciences Inc has shown variability, reflecting the company's ability to manage its costs and generate profits before tax obligations.
Peer comparison
Dec 31, 2024